Abstract: The present invention relates to a complex for promoting cartilage differentiation comprising stem cells or a culture thereof and a cartilage cell-free crush, a method for fabricating cartilage by using the complex, cartilage fabricated via the method, a pharmaceutical composition comprising the complex for preventing or treating arthropathy, a method for preventing or treating arthropathy using the composition, a composition for inducing cartilage cell differentiation comprising the prepared cartilage cells, and a method for fabricating cartilage using the prepared cartilage cells.

Abstract: Provided is a pharmaceutical composition for preventing or treating Asherman's syndrome or complications thereof, comprising mitochondria as an active ingredient. The pharmaceutical composition alleviates or treats endometrial adhesion, and may alleviate or treat endometrial fibrosis. Therefore, the pharmaceutical composition may be effectively used in the treatment and prevention of diseases such as endometrial adhesion disease, particularly Asherman's syndrome, and thus is highly industrially applicable.

Abstract: The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting device comprising the same.

Abstract: The present specification provides a heterocyclic compound represented by Chemical Formula 1, an organic light emitting device comprising the same, a composition for an organic material layer of an organic light emitting device, and a method for manufacturing an organic light emitting device.

Abstract: An apparatus for controlling temperature and pressure may include: a shaft installed in an aircraft, the shaft being rotatable by having a motor coupled thereto; a compressor, rotatable by being connected to the shaft, configured to form a flow of heated compressed air by compressing external air introduced into the aircraft; a heat exchanger configured to heat-exchange the heated compressed air with a portion of external air introduced into the aircraft; a turbine, rotatable by being connected to the shaft, configured to form a flow of cooling air by expanding the heat-exchanged compressed air; and a cooling heat exchanger configured to exchange heat between a refrigerant cooling a fuel cell power train in the aircraft and the cooling air.

Abstract: An environmental control device includes a shaft installed in an aircraft and coupled to a motor to be rotatable; a compressor connected to the shaft to be rotatable, the compressor adiabatically compressing external air introduced into the aircraft to form a flow of compressed air having a raised temperature; a heat exchanger allowing heat exchange between the compressed air having a raised temperature and a portion of the external air introduced into the aircraft; and a turbine connected to the shaft to be rotatable, the turbine adiabatically expanding the heat-exchanged compressed air to form a flow of chilling air.

Abstract: A power supply system for an aircraft and a control method thereof are provided. The power supply system of the aircraft includes a fuel cell configured to generate electrical energy, a converter device configured to supply a voltage generated by the fuel cell to a first motor device for driving the aircraft through a first output terminal and switch a connection with the fuel cell depending on a predetermined driving mode, a battery configured to supply the voltage to a second motor device for driving the aircraft through a second output terminal, the second output terminal being connected with an output node of the fuel cell, and a processor configure to control a connection between the fuel cell and the converter device depending on the driving mode.

Abstract: Disclosed is a method for manufacturing a sulfide-based solid electrolyte, the method including: providing a sulfide-based compound; adding the sulfide-based compound to a silicone oil, followed by milling; and drying the milled sulfide-based compound.

Abstract: There is disclosed a posture analysis system using a smart mirror and a camera. The posture analysis system includes a smart mirror configured to reflect a posture of a user, a camera module configured to photograph the posture of the user and generate a posture image, a posture recognition module configured to recognize the posture image generated by the camera module, an image storage control module configured to automatically perform control to store the posture image, an image storage module configured to store the posture image by automatic control of the image storage control module, and a user balance analysis module configured to perform a posture balance analysis of the user using the posture image stored in the image storage module. The posture analysis system described above is configured to photograph and analyze the user's original, uncorrected posture with the eyes closed, and thereby, has an effect of accurately analyzing postures of shoulders, pelvis, arms, legs, and the like of the user.

Abstract: A new use of estrogen-related receptor ? (ERR?) inhibitor in enhancing cancer treatment and a pharmaceutical composition for inhibiting the resistance of cancer to tyrosine kinase inhibitors and enhancing an anticancer effect are disclosed. The pharmaceutical composition contains an ERR? inhibitor as an active ingredient. The pharmaceutical composition for treating tyrosine kinase inhibitor-resistant advanced cancer. The composition can be administered in combination with tyrosine kinase inhibitor. A method for determining if a cancer is tyrosine kinase-resistant is also disclosed.

Abstract: A fingerprint recognition package may include a circuit board; an image sensor die attached and electrically connected to the circuit board; a light-shielding member applied to the circuit board; and an adhesive member attached to one side of the light-shielding member. The light-shielding member can be cured by being irradiated with ultraviolet rays, and can be thermoset by being irradiated with heat.

Abstract: The present invention relates to a pharmaceutical composition for inhibiting the resistance of liver cancer to sorafenib and enhancing an anticancer effect, comprising an Estrogen-related receptor ? (ERR?) inhibitor as an active ingredient. The present invention can be effectively used as a pharmaceutical composition for treating sorafenib-resistant advanced liver cancer.

Abstract: The present invention relates to a pharmaceutical composition for the treatment of sepsis or systemic inflammatory response syndrome (SIRS) comprising mitochondria as effective ingredient. When activated macrophages and monocytes are treated with mitochondria which are effective ingredient of the pharmaceutical composition of the present invention, expression of IL-1?, TNF-? and IL-6 which are pro-inflammatory cytokines can be restored to normal levels. Furthermore, when the pharmaceutical composition of the present invention is administered to a subject suffering from sepsis, the survival rate of the subject can be remarkably increased. Therefore, the pharmaceutical composition according to the present invention can be useful for the treatment of sepsis.

Abstract: The present specification relates to a multicyclic compound represented by Chemical Formula 1, and an organic light emitting device including the same.

Abstract: The present invention relates to compounds represented by specific formulas, organic optoelectronic diodes, and display devices.

Abstract: The present specification provides a heterocyclic compound represented by Chemical Formula 1, an organic light emitting device comprising the same, a composition for an organic material layer of an organic light emitting device, and a method for manufacturing an organic light emitting device.

Abstract: Disclosed are a pharmaceutical composition containing isolated mitochondria as an effective component and uses of the composition. The pharmaceutical composition can restore the ATP synthesis capacity and antioxidant capacity of tenocytes damaged by inflammations to a normal tenocyte level. In addition, the pharmaceutical composition, when administered to damaged tenocytes, inhibits the expression of an apoptosis promoter, Bax, and increases the expression of an apoptosis inhibitor, Bcl-2. In addition, the pharmaceutical composition, when administered to damaged tenocytes, can restore the expression of MMP1 to a normal tenocyte level. Accordingly, uses of the pharmaceutical composition include prevention or treatment of tendinopathy in a subject.

Abstract: Mitochondria modified by a targeting protein, according to one embodiment of the present invention, can be effectively delivered to a target. In addition, when a protein of interest bound to the modified mitochondria is delivered into a cell, various activities can be exhibited. The modified mitochondria can effectively cause cancer tissue death, and thus can also be used as an anticancer agent. Furthermore, various activities are exhibited according to a protein of interest loaded on modified mitochondria, and thus the modified mitochondria can be applied in the treatment of various diseases. Additionally, a fusion protein comprising a protein of interest and a fusion protein comprising a targeting protein, according to one embodiment of the present invention, can be used in order to modify mitochondria. Moreover, mitochondria modified with the fusion proteins exhibits various effects in a target cell.

Abstract: The present application provides a hetero-cyclic compound which may significantly improve the service life, efficiency, electrochemical stability, and thermal stability of an organic light emitting device, and an organic light emitting device in which the hetero-cyclic compound is contained in an organic compound layer.

Abstract: An operation method for an instant messenger server is provided. The method includes generating a schedule which depends on an account of a host in response to a schedule generation request of the host, determining invitees based on at least one of a chat room list and a friend list of the account of the host, synchronizing schedules which depend on accounts of users who participate in the schedule, based on whether at least one guest included in the invitees participates, and providing a notification of the schedule to at least one of the users who participate in the schedule, through a user interface (UI) of a chat room provided through the instant messaging service.